To include your compound in the COVID-19 Resource Center, submit it here.

FDA to discuss Xifaxan for IBS

Salix Pharmaceuticals Ltd. (NASDAQ:SLXP) said an FDA advisory committee will meet in November to discuss an sNDA for Xifaxan rifaximin 550

Read the full 212 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE